Mass Spectrometry in Drug Discovery: Covalent and Non-Covalent Screening Applications
Identifying small-molecule binders for complex biological targets remains a major challenge in early drug discovery, particularly when working with membrane proteins or large protein complexes. Mass spectrometry (MS)–based screening approaches are increasingly used to address these challenges, but they can present technical limitations and experimental design considerations.
In this webinar, Dr. Johann Stojko, experienced biophysicist at Novalix, will present integrated workflows that combine covalent fragment screening and non-covalent binder detection to support hit discovery and validation.
Through practical case studies, attendees will see how complementary MS strategies can help improve confidence in screening results and accelerate progression from hit identification to lead optimization.
Attend this webinar to:
- Understand the screening approaches developed at Novalix
- Explore workflows used to address challenging targets, including membrane proteins and protein complexes
- Identify the limitations and advantages of each technique
- Learn how experimental design and appropriate controls can improve confidence in MS screening results
Speaker: Johann Stojko, PhD (Senior Project Manager, Novalix)
Speaker: François Debaene (Head of Mass Spectrometry, Novalix)
